Illinois Municipal Retirement Fund Invests $1.02 Million in Perrigo Company plc $PRGO

Illinois Municipal Retirement Fund bought a new position in shares of Perrigo Company plc (NYSE:PRGO) in the first quarter, HoldingsChannel reports. The fund bought 94,646 shares of the company’s stock, valued at approximately $1,016,000.

Other large investors have also recently bought and sold shares of the company. SG Americas Securities LLC lifted its stake in Perrigo by 1,495.6% during the fourth quarter. SG Americas Securities LLC now owns 134,433 shares of the company’s stock worth $1,871,000 after purchasing an additional 126,008 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Perrigo by 7.9% in the fourth quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock valued at $208,568,000 after purchasing an additional 1,101,154 shares in the last quarter. Sound Income Strategies LLC increased its stake in Perrigo by 58.6% in the fourth quarter. Sound Income Strategies LLC now owns 1,138,357 shares of the company’s stock valued at $17,110,000 after purchasing an additional 420,626 shares during the last quarter. Thompson Siegel & Walmsley LLC raised its holdings in Perrigo by 28.4% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 4,658,601 shares of the company’s stock worth $64,848,000 after purchasing an additional 1,029,770 shares in the last quarter. Finally, Gamco Investors INC. ET AL raised its holdings in Perrigo by 26.0% during the fourth quarter. Gamco Investors INC. ET AL now owns 1,077,785 shares of the company’s stock worth $15,003,000 after purchasing an additional 222,287 shares in the last quarter. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Perrigo Trading Up 0.4%

NYSE:PRGO opened at $10.51 on Thursday. The stock’s 50 day moving average price is $10.63 and its 200 day moving average price is $11.83. The company has a market capitalization of $1.45 billion, a PE ratio of -0.80, a P/E/G ratio of 1.24 and a beta of 0.51. The company has a quick ratio of 1.59, a current ratio of 2.72 and a debt-to-equity ratio of 1.45. Perrigo Company plc has a 52-week low of $9.23 and a 52-week high of $28.43.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. The company had revenue of $841.80 million for the quarter, compared to analyst estimates of $1.04 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The firm’s revenue was down 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.60 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, research analysts anticipate that Perrigo Company plc will post 2.11 EPS for the current year.

Perrigo Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Investors of record on Friday, May 29th were given a $0.29 dividend. The ex-dividend date was Friday, May 29th. This represents a $1.16 annualized dividend and a yield of 11.0%. Perrigo’s dividend payout ratio is -8.85%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on PRGO shares. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings upgraded shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $19.33.

Perrigo Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.